TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06549465: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant

Sponsor: Convergent Therapeutics · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 93 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,755,600

Rescue Site Savings

+$1,155,000

Unlock Full NCT06549465 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06549465 Rescue Dossier →